Table 4

Statistical analyses of the hyperlocomotor effects of oxycodone, morphine, and cocaine in all lines ( Fig. 3)

ItemFigureExperimentStatistical testEffect or InteractionMain effectflMORD1flMORD2flMORA2aflMORChATflMOR
a 3A Oxycodone dose response: dose response (0 mg/kg or saline)One-way ANOVAGenotypeF(4,36) = 2.54, p = 0.056Reference genotype n = 8N.S. n = 8N.S. n = 8N.S. n = 8N.S. n = 9
b 3A Oxycodone dose response: dose effectTwo-way ANOVAGenotype × doseF(12,145) = 3.76, p < 0.0013 mg; p = 0.007 vs 0, 10 mg; p = 0.0002 vs 0 n = 8–12N.S. n = 8–113 mg; p = 0.56 vs 0, 10 mg; p < 0.0001 vs 0, n = 83 mg; p < 0.0001 vs 0, 10 mg; p < 0.0001 vs 0, n = 6–93 mg; p = 0.80 vs 0, 10 mg; p = 0.0013 vs 0 n = 5–9
c 3A Oxycodone dose response: genotype effectTwo-way ANOVAGenotype × doseF(12,145) = 3.76, p < 0.001Reference genotype10 mg: p = 0.04N.S.3 mg; p = 0.0001, 10 mg; p < 0.0001N.S.
d 3B Morphine dose response: dose effectTwo-way ANOVAGenotype × doseF(12,148) = 5.7, p < 0.00110 mg; N.S. 15 mg; p = 0.003 vs 0 n = 8–11N.S. n = 8–1110 mg; N.S. 15 mg; p < 0.0001 n = 8–1110 mg; p < 0.0001, 15 mg; p < 0.0001 n = 5–9N.S. n = 6–9
e 3B Morphine dose response: genotype effectTwo-way ANOVAGenotype × doseF(12,148) = 5.7, p < 0.001Reference genotype15 mg: p = 0.004N.S.10 mg; p = 0.0001, 15 mg; p = 0.004N.S.
f 3C Cocaine; dose effectTwo-way ANOVATreatment × genotypeF(4,83) = 3.77, p = 0.0073p < 0.0001 Cocaine, n = 21; saline n = 9p = 0.0018 Cocaine, n = 9; saline n = 14p = 0.0010 Cocaine, n = 9; saline n = 7p = 0.0005 Cocaine, n = 9; saline n = 9p < 0.0001 Cocaine, n = 10; saline n = 7
g 3C Cocaine; genotype effectTwo-way ANOVATreatment × genotypeF(4,83) = 3.77, p = 0.0073Reference genotypeN.S. for saline and cocaineN.S. for saline and cocaineN.S. for saline and cocaineSaline; N.S. Cocaine; p < 0.0005
h 3D Locomotor sensitization; flMORsTwo-way ANOVAGenotype × dayF(2,27) = 3.9, p = 0.049Oxycodone; p = 0.002 morphine; p = 0.018 n = 11 for both, saline n = 8
i 3E Locomotor sensitization; D1flMORsTwo-way ANOVAGenotype × dayF(2,25) = 0.6, p = 0.56N.S. oxycodone n = 8, morphine n = 11, saline n = 8
j 3F Locomotor sensitization; D2flMORsTwo-way ANOVAGenotype × dayF(2,23) = 12.24, p = 0.0002Oxycodone; p < 0.0001, n = 7, morphine; p < 0.0001 n = 11,
saline n = 8
k 3G Locomotor sensitization; A2aflMORsTwo-way ANOVAGenotype × dayF(2,25) = 8.23, p = 0.0018Oxycodone; p < 0.0001 n = 11,
morphine; p = 0.15, n = 9, saline n = 8
l 3H Locomotor sensitization; ChATflMORsTwo-way ANOVAGenotype × dayF(2,23) = 11.53, p = 0.0003Oxycodone; p < 0.0001, n = 8, morphine; N.S., n = 9, saline; n = 9
m 3I Oxycodone intrasession analysis: Day 1LMMGenotype × timebinχ2 = 11.882,
p = 0.018
N.A.N.S., n = 9N.S., n = 8N.S., n = 11N.S., n = 9
n 3J Oxycodone intrasession analysis: day 1LMMTimebinχ2 = 31.215,
p < 0.0001
N.S., n = 11p = 0.076, n = 9p = 0.016, n = 8p < 0.0001, n = 11N.S., n = 9
o 3K Oxycodone intrasession analysis: day 3LMMGenotype × timebinN.S.N.A.N.S., n = 9N.S., n = 8N.S., n = 11N.S., n = 9
p 3K Oxycodone intrasession analysis: day 3LMMTimebinχ2 = 12.66,
p = 0.027
N.S., n = 11p < 0.001, n = 9N.S., n = 8N.S., n = 11N.S., n = 9
q 3L Morphine intrasession analysis: day 1LMMGenotype × timebinχ2 = 21.239,
p < 0.001
N.A.p = 0.002N.S.N.S.N.S.
r 3L Morphine intrasession analysis: day 1LMMTimebinχ2 = 54.796,
p < 0.0001
p < 0.0001N.S.,
p = 0.79
p < 0.0001p < 0.0001p = 0.002
s 3M Morphine intrasession analysis: day 3LMMGenotype × timebinχ2 = 32.962,
p < 0.0001
N.A.p < 0.0001N.S.N.S.p < 0.0001
t 3M Morphine intrasession analysis: day 3LMMTimebinχ2 = 64.194,
p < 0.0001
p < 0.0001N.S.,
p = 0.56
p < 0.0001p < 0.0001p = 0.03
  • N.S.: not significant, N.A: not applicable.